Nawid Albinger

548 total citations
9 papers, 349 citations indexed

About

Nawid Albinger is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Nawid Albinger has authored 9 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Nawid Albinger's work include CAR-T cell therapy research (8 papers), Immune Cell Function and Interaction (7 papers) and RNA Interference and Gene Delivery (2 papers). Nawid Albinger is often cited by papers focused on CAR-T cell therapy research (8 papers), Immune Cell Function and Interaction (7 papers) and RNA Interference and Gene Delivery (2 papers). Nawid Albinger collaborates with scholars based in Germany and United Kingdom. Nawid Albinger's co-authors include Evelyn Ullrich, Jessica Hartmann, Tobias Bexte, Olaf Penack, Sarah Mertlitz, Congcong Zhang, Michael W.M. Kühn, Ralf Schubert, Hermann Kreyenberg and Dina Schneider and has published in prestigious journals such as Blood, Frontiers in Immunology and Gene Therapy.

In The Last Decade

Nawid Albinger

9 papers receiving 341 citations

Peers

Nawid Albinger

ONCOL

IMMUN

MB

GENET

HEMAT

Rebecca Wijers Netherlands

Paul Shafer United States

Gils Roex Belgium

Antonio Valeri Spain

Haven R. Garber United States

Samuel John United States

Kevin M. Friedman United States

Chengfei Pu China

Anja Waldmann Germany

Wenhong Shen China

Rebecca Wijers Netherlands

Nawid Albinger

245 ×0.9

ONCOL

174 ×0.8

IMMUN

89 ×0.8

MB

31 ×0.5

GENET

28 ×0.6

HEMAT

Citations per year, relative to Nawid Albinger Nawid Albinger (= 1×) peers Rebecca Wijers

Countries citing papers authored by Nawid Albinger

Since Specialization

Citations

This map shows the geographic impact of Nawid Albinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nawid Albinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nawid Albinger more than expected).

Fields of papers citing papers by Nawid Albinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nawid Albinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nawid Albinger. The network helps show where Nawid Albinger may publish in the future.

Co-authorship network of co-authors of Nawid Albinger

This figure shows the co-authorship network connecting the top 25 collaborators of Nawid Albinger. A scholar is included among the top collaborators of Nawid Albinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nawid Albinger. Nawid Albinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Albinger, Nawid, Sabine Müller, Sarah Mertlitz, et al.. (2024). Manufacturing of primary CAR-NK cells in an automated system for the treatment of acute myeloid leukemia. Bone Marrow Transplantation. 59(4). 489–495. 21 indexed citations

2.

Albinger, Nawid, Jordis Trischler, Christine Heller, et al.. (2024). Immune profiling and functional analysis of NK and T cells in ataxia telangiectasia. Frontiers in Immunology. 15. 1377955–1377955. 1 indexed citations

3.

Albinger, Nawid, Tobias Bexte, Jamal Alzubi, et al.. (2023). P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.. HemaSphere. 7(S3). e71265f8–e71265f8. 1 indexed citations

4.

Albinger, Nawid, Sarah Mertlitz, Hermann Kreyenberg, et al.. (2022). Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer Journal. 12(4). 61–61. 70 indexed citations

5.

Albinger, Nawid, et al.. (2022). Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Klinische Pädiatrie. 234(3). 181–181. 2 indexed citations

6.

Albinger, Nawid, Tobias Bexte, Jamal Alzubi, et al.. (2022). CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML. Blood. 140(Supplement 1). 4558–4559. 16 indexed citations

7.

Albinger, Nawid, Jessica Hartmann, & Evelyn Ullrich. (2021). Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy. 28(9). 513–527. 178 indexed citations

8.

Bexte, Tobias, Nawid Albinger, Andréas Mackensen, et al.. (2021). Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. Cancers. 13(6). 1481–1481. 28 indexed citations

9.

Albinger, Nawid, et al.. (2020). Immunotherapy with NK cells: recent developments in gene modification open up new avenues. OncoImmunology. 9(1). 1777651–1777651. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact